Commercial Credit Report for Reunion Neuroscience, Inc.

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Reunion Neuroscience, Inc. is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Reunion Neuroscience, Inc.
30 Duncan Street, Suite 401
Lower North Level
Phone: 833-222-0084p:833-222-0084	TORONTO, ON M5V 2C3 Canada

This company ceased filing statements with the SEC on 8/18/2023.
On 8/1/2023, the Company completed its plan of arrangement with MPM BioImpact
This company is no longer actively traded on any major stock exchange.

Business Summary

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

(Source: PRESS)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
3/31/2023	3/31/2023	Yes	Yes	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8000	Health services

Officers and Directors

Title	Name	Title Date	Start Date
Executive Chairman of the Board	RonanLevy	4/1/2019	4/1/2019
President, Director	HannanFleiman	4/1/2019	4/1/2019
Chief Executive Officer, Director	JosephDel Moral	4/1/2019	4/1/2019
10 additional Officers and Directors records available in full report.

Business Names

Business Name
Field Trip Psychedelics Inc.
Newton Energy Corporation
NX Capital Corp.
Octane Energy Services Ltd.

General Information

Outstanding Shares:	11,717,616	(As of 6/13/2023)
Shareholders:	5,876
Stock Exchange:	TSE
Email Address:	investors@reunionneuro.com

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN